AASLD 2025 | SOLSTICE Phase 2 Trial
Tobevibart (anti-HBsAg mAb) ± Elebsiran (siRNA) in chronic #HepatitisD:
✅ Week 48 undetectable HDV RNA: 66% (combo) vs 48% (monotherapy)
✅ HBsAg < 10 IU/mL: 91% vs 21%
💉Safe & well-tolerated; no ALT flares.
A promising dual HBV/HDV targeted approach.
Gần 2500 bệnh nhân viêm gan B tại Việt Nam sẽ được xét nghiệm viêm gan D miễn phí theo tiêu chuẩn Mỹ. Đây là chương trình nghiên cứu quy mô lớn đầu tiên về viêm gan D do Viện Nghiên cứu Tâm Anh thực hiện, nhằm mục tiêu phát minh thuốc đặc trị cho bệnh nhân.
#ViêmGanD #HepatitisD
#NghiênCứuYHọc #MedicalResearch
#SứcKhỏe #Health
#ViệtNam #Vietnam
Viện Nghiên cứu Tâm Anh phối hợp cùng Viện Vi sinh và Chống dịch Stanford (Mỹ) triển khai nghiên cứu HEP-D – lần đầu tiên tại Việt Nam thực hiện xét nghiệm tầm soát viêm gan D đạt chuẩn quốc tế. Gần 2.500 bệnh nhân viêm gan B sẽ được xét nghiệm miễn phí để đánh giá nguy cơ mắc viêm gan D, một biến thể nguy hiểm của viêm gan B.
#Health #SứcKhỏe #ViêmGanD #HepatitisD #TâmAnh #Stanford #XétNghiệmMiễnPhí #MedicalResearch #NghiênCứuYKhoa
Deltaviruses spread through a viral Trojan Horse.
#Virology #Deltaviruses #HepatitisD #HelperViruses #ViralSatellites #Preprint
Hepatitis D-like viral satellites, known as deltaviruses, have been recently discovered in a wide range of animals. These viruses are thought to expropriate glycoproteins from helper viruses to form infectious particles. Here, we challenge this paradigm and demonstrate that deltaviruses are packaged within helper virus particles, using them as viral Trojan Horses for cell entry. By leveraging orthogonal electronic and photonic super-resolution microscopy, we visualize deltaviruses enclosed within virions from rhabdo-, herpes-, and arenavirus families. We show that this conserved hitchhiking mechanism ensures concomitant deltavirus-helper virus spread, which advantages the dissemination of deltaviruses, broadens their host range and expands their tropism. Our findings reveal a previously unrecognized mode of viral transmission, providing a framework to investigate overlooked deltavirus infections outside of the human liver. ### Competing Interest Statement The authors have declared no competing interest. European Research Council, 101039538 DELV
Hola Titánicos, cada 29 de julio se celebra el día mundial de la hepatitis, una inflamación del hígado cuando éste se lesionan o infecta.
Descubre como puede afectar a cada persona.
https://somosdisca.es/dia-mundial-contra-la-hepatitis-2024/
#hepatitis #DiaMundialContraLaHepatitis #HepatitisDay #HepatitisD #hepatitisvirica #hepatitisA #hepatitisC #HepatitisB #visibilidad #salud #enfermedad #prevencion #cuidados #discapacidad #disablity #disabilities #titanicos #titan #titanico #gentetitanica #somosdisca
Referenced link: https://medicalxpress.com/news/2023-03-real-world-effectiveness-bulevirtide-chronic-hepatitis.html
Discuss on https://discu.eu/q/https://medicalxpress.com/news/2023-03-real-world-effectiveness-bulevirtide-chronic-hepatitis.html
Originally posted by Phys.org / @physorg_com: http://nitter.platypush.tech/medical_xpress/status/1637883220350869505#m
RT by @physorg_com: Real-world studies confirm effectiveness of bulevirtide to treat chronic ##hepatitisD https://linkinghub.elsevier.com/retrieve/pii/S0168827822029804 https://medicalxpress.com/news/2023-03-real-world-effectiveness-bulevirtide-chronic-hepatitis.html
In 2020, bulevirtide (BLV) was conditionally approved for treating chronic hepatitis delta (CHD), an inflammation of the liver caused by hepatitis D virus (HDV). Now real-world studies of patients treated outside of clinical trials confirm that long-term suppressive therapy with BLV monotherapy has the potential to reduce viral replication and improve liver tests of these difficult-to-treat patients for the first time in 45 years, report investigators in the Journal of Hepatology and its companion journal JHEP Reports.
GastroAGI
VTC News Bot
Innovative Health Initiative
Amelia Cervera 🧬
Somosdisca 
Phys.org